Effects of laughter therapy in patients with cancer: A systematic review of randomized clinical trials.

Complement Ther MedJun 24, 2026 (epub)
Clinical ResearchOncology (Medical)

Fritzi Pilar Villalba-Ugarte, Raúl H Sandoval-Ato, Jamee Guerra Valencia et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review of randomized controlled trials evaluated the effects of laughter therapy in 1127 cancer patients. The findings suggest that laughter therapy probably leads to a significant reduction in anxiety (SMD: -0.54, 95% CI: -0.84 to -0.24) and may reduce pain and stress, although evidence for other outcomes remains uncertain.

Key findings

  • Laughter therapy probably reduces anxiety with a standardized mean difference of -0.54.
  • It probably results in little to no difference in quality of life (MD: -0.65).
  • Laughter therapy may lead to an important reduction in pain and stress.
  • Evidence regarding depressive symptoms and fatigue is very uncertain.

Why it matters

Understanding the potential benefits of non-pharmacological interventions like laughter therapy can help clinicians support cancer patients' psychological well-being and improve their overall treatment experience.

What to keep in mind

The review notes limitations related to risk of bias, heterogeneity among interventions, and imprecision due to small sample sizes.

Source

Published in Complement Ther Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.